Rebetol and Increased upper airway secretion - a phase IV clinical study of FDA data

Summary:

Increased upper airway secretion is found among people who take Rebetol, especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months.

The phase IV clinical study analyzes which people take Rebetol and have Increased upper airway secretion. It is created by eHealthMe based on reports of 25,882 people who have side effects when taking Rebetol from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

25,882 people reported to have side effects when taking Rebetol.
Among them, 21 people (0.08%) have Increased upper airway secretion.

What is Rebetol?

Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,907 Rebetol users for its effectiveness, alternative drugs and more.

What is Increased upper airway secretion?

Increased upper airway secretion is found to be associated with 1,088 drugs and 611 conditions by eHealthMe.

Number of Rebetol and Increased upper airway secretion reports submitted per year:

Could Rebetol cause Increased upper airway secretion?

Time on Rebetol when people have Increased upper airway secretion *:

Gender of people who have Increased upper airway secretion when taking Rebetol *:

female: 31.58 %
male: 68.42 %

Age of people who have Increased upper airway secretion when taking Rebetol *:

Common drugs people take besides Rebetol *:

Common side effects people have besides Increased upper airway secretion *:

Cough: 12 people, 57.14%
Fatigue (feeling of tiredness): 11 people, 52.38%
Weakness: 10 people, 47.62%
Breathing Difficulty: 9 people, 42.86%
Dizziness: 7 people, 33.33%
Rashes (redness): 6 people, 28.57%
Memory Loss: 6 people, 28.57%
Influenza Like Illness: 6 people, 28.57%
Weight Decreased: 5 people, 23.81%
Chest Pain: 5 people, 23.81%

Common conditions people have *:

Hepatitis C: 19 people, 90.48%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Rebetol and have Increased upper airway secretion?

Check whether Increased upper airway secretion is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

Related studies

How severe was Increased upper airway secretion and when was it recovered:

Increased upper airway secretion in Rebetol

Expand to all the drugs that have ingredients of ribavirin:

Increased upper airway secretion and drugs with ingredients of ribavirin (112 reports)

Alternative drugs to, pros and cons of Rebetol:

Rebetol (25,907 reports)

Common Rebetol side effects:

Fatigue (feeling of tiredness): 2,064 reports
Rashes (redness): 1,812 reports
Thrombocytopenia (decrease of platelets in blood): 1,709 reports
Fever: 1,629 reports
Weakness: 1,422 reports
Depression: 1,377 reports

Browse all side effects of Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Increased upper airway secretion treatments and more:

Increased upper airway secretion (6,456 reports)

COVID vaccines that are related to Increased upper airway secretion:

Common drugs associated with Increased upper airway secretion:

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Rebetol) and Rebetol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.